drugset / Trial / NCT00144508
Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA)
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate clinical efficacy and tolerability of MRA, patients with RA are randomized to receive either MRA or conventional DMARDs.
Timeline
- Start
- 2003-03
- Primary completion
- 2004-05
- Completion
- 2006-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tocilizumab | Monoclonal antibody | 8 mg/kg | — |